Somatic Mutation | Solid Tissue Molecular Profiling in Thyroid Cancer
Thyroid Cancer Test Panel (DNA)
In anaplastic thyroid cancer (ATC), BRAF p.V600E mutation occurs in ~40% of patients with papillary thyroid carcinoma (PTC) and is associated with a more aggressive disease1,2.
Genes sequenced in this panel include:
| BRAF | KRAS |
| NRAS | RET |
Test cost: No Medicare rebate available.
Medullary Thyroid Cancer (MTC) Panel
Medullary thyroid cancer (MTC) is associated with oncogenic mutations in RET (40-60%) that can be targeted by therapeutic treatments3.
Genes sequenced in this panel include:
| Oncogenic mutations in RET |
Test cost: No Medicare rebate available.
When to Order: At diagnosis or on therapy for treatment selection.
How to Order: Fill out our Somatic Mutation testing request form.
Turnaround Time: 5-7 business days from the sample receipt date.
Specimen Required: Fresh formalin-fixed paraffin-embedded (FFPE) of 5-10 μm thickness from the tumour tissue.
Test Cost: Thyroid Cancer Test Panel (DNA): No Medicare rebate available.
Medullary Thyroid Cancer (MTC) Panel: No Medicare rebate available.
References
1. Cohen Y et al., (2004) Clin Cancer Res 10(8):2761–2765.
2. Xing M et al., (2005) J Clin Endocrinol Metab 90(12):6373–6379.
3. Malone E et al., Genome Medicine (2020). Molecular profiling for precision cancer therapies 12:8.
Download Somatic Mutation Brochure
Download Somatic Mutation Request Form Download Somatic Mutation Request Form - WA
The content on our Molecular Cancer Services page is written by Associate Professor Mirette Saad, National Director of Molecular Genetics at Australian Clinical Labs.
 |
Assoc. Prof. Mirette SaadMBBS (Hons), MD, MAACB, FRCPA, PhD |
Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from Suez Canal University, Egypt. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for non-invasive prenatal testing (NIPT), antenatal screening, personalised drug therapy and cancer.